LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Notably, the Huntsville site will be among those that will manufacture orforglipron, Lilly’s first oral, small molecule GLP-1 ...

Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...

Expanding Lilly’s U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests ...

Major pharmaceutical manufacturer Eli Lilly and Company is building a $6 billion plant in the Tennessee Valley.